TherapeuticsMD (TXMD) AI Stock Analysis

• Market Cap: $13.31M
• Dividend Yield: N/A
• Average Volume (3M): 36.13K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.56
• Revenue Growth: 35.25%
• EPS Growth: 81.05%
• Country: US
• Employees: 1
• Sector: Healthcare
• Sector Strength: 37
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.06
• Shares Outstanding: 11,574,362
• 10 Day Avg. Volume: 20,973
• 30 Day Avg. Volume: 36,131
• PEG Ratio: N/A
• Price to Book (P/B): 0.49
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 8.50
• Enterprise Value/Market Cap: 1.00
• Enterprise Value/Revenue: 2.16
• Enterprise Value/Gross Profit: 7.67
• Enterprise Value/Ebitda: -1.07
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 47 Neutral
• Price Target: ―

TherapeuticsMD is undergoing significant challenges, with financial difficulties being the primary concern due to declining revenues and profitability issues. The technical analysis indicates some short-term momentum but struggles over the longer term. Valuation metrics are not attractive, with a negative P/E ratio and no dividend yield. Corporate events provide a glimmer of hope, with reduced losses and strategic initiatives suggesting potential future improvements. However, the overall outlook remains cautious.

TherapeuticsMD Business Overview & Revenue Model

Company Description

TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

How the Company Makes Money

TherapeuticsMD generates revenue primarily through the sale of its pharmaceutical products. The company's key revenue streams include the sales of its FDA-approved hormone therapy products and prenatal vitamins. TherapeuticsMD also engages in partnerships with healthcare providers and pharmacies to distribute its products, enhancing its market reach and accessibility. Additionally, the company may engage in licensing agreements and collaborations with other pharmaceutical companies to leverage its research and development capabilities, thus contributing to its earnings.

TherapeuticsMD Financial Statement Overview

Summary

TherapeuticsMD's financial statements reveal a company facing significant financial difficulties. The income statement reflects ongoing challenges with revenue generation and profitability. The balance sheet shows improved equity but remains strained by liabilities. Cash flow statements indicate some recovery in free cash flow, but historical volatility persists. The company must address these challenges to improve its financial health and stability.

Income Statement

TherapeuticsMD has faced declining revenues, with Total Revenue dropping to zero in the latest annual report. The company has consistently reported negative EBIT and net income, indicating ongoing operational challenges. Despite previous periods of profitability, recent financials show significant losses, resulting in a low score.

Balance Sheet

The company's balance sheet shows high leverage with a debt-to-equity ratio of approximately 0.20 in the latest period. While stockholders' equity has improved from negative in earlier years, the overall financial health remains weak due to high liabilities relative to assets. This balance of negative and positive factors results in a moderate score.

Cash Flow

There has been a significant improvement in free cash flow, transitioning from negative to positive in the most recent year. However, the company's operating cash flow has fluctuated significantly over the years. The improvements in free cash flow provide a slightly better outlook but overall cash flow stability remains a concern, leading to a moderate score.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.76M	1.30M	69.96M	86.95M	64.87M
Gross Profit	1.25M	380.00K	68.57M	68.11M	48.90M
EBITDA	-1.83M	-8.40M	11.86M	-78.57M	-149.47M
Net Income	-2.18M	-10.28M	112.00M	-205.60M	-212.70M
Balance Sheet
Total Assets	38.82M	43.31M	90.46M	169.47M	181.61M
Cash, Cash Equivalents and Short-Term Investments	5.06M	4.33M	38.07M	65.12M	80.49M
Total Debt	7.17M	8.01M	8.76M	196.33M	246.37M
Total Liabilities	11.45M	14.02M	55.31M	263.09M	305.61M
Stockholders Equity	27.37M	29.29M	35.14M	-93.62M	-124.00M
Cash Flow
Free Cash Flow	1.17M	-48.14M	-4.43M	-144.92M	-161.07M
Operating Cash Flow	1.17M	-48.14M	-4.08M	-142.69M	-159.47M
Investing Cash Flow	0.00	0.00	223.48M	-2.22M	-1.60M
Financing Cash Flow	0.00	3.15M	-235.21M	129.55M	80.72M

TherapeuticsMD Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.14
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TXMD, the sentiment is Negative. The current price of 1.14 is below the 20-day moving average (MA) of 1.16, below the 50-day MA of 1.25, and below the 200-day MA of 1.20, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 44.48 is Neutral, neither overbought nor oversold. The STOCH value of 47.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TXMD.

TherapeuticsMD Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AYTU	65 Neutral	$14.62M	―	3.29%	―	-26.17%	―
Sector *	52 Neutral	$7.45B	-0.04	-63.76%	2.49%	16.24%	<0.01%
BFRI	49 Neutral	$8.94M	―	-384.98%	―	14.27%	87.31%
PRPH	48 Neutral	$15.18M	―	-58.71%	―	-79.66%	-141.87%
TXMD	47 Neutral	$13.31M	―	-7.72%	―	35.25%	81.05%
COSM	47 Neutral	$12.88M	―	-58.30%	―	―	―
KALA	31 Underperform	$37.04M	―	-576.46%	―	―	38.50%

TherapeuticsMD Corporate Events

TherapeuticsMD Reports Reduced Losses and Revenue Growth

TherapeuticsMD reported a net loss from continuing operations of $2.3 million for the year ending December 31, 2024, a significant improvement from the previous year’s loss of $7.7 million. The company experienced a 35.3% increase in license revenue, primarily due to the Mayne License Agreement, and reduced its operating expenses by 33.6% as it continues to transition from a commercial business to a royalty-based model. TherapeuticsMD is also exploring strategic alternatives, including potential mergers or acquisitions, though no specific outcomes or timelines have been established.